Practical Solutions Across the Spectrum of Care - The Aging HIV Population: Comorbidity Roll Call

This activity is jointly provided by Postgraduate Institute for Medicine and Integritas Communications.

Supported by an independent educational grant from Gilead Sciences, Inc. 

Release date: November 12, 2020

Expiration date: January 5, 2022

Estimated time to complete activity: 0.5 hours

TARGET AUDIENCE

This activity is intended for infectious disease and HIV specialist physicians and other clinicians involved in the care of patients with HIV infection.

EDUCATIONAL OBJECTIVES

Upon completion of this program, the participant should be better able to:

• Recognize common comorbidities and polypharmacy issues in aging patients with HIV
• Participate in multidisciplinary care to optimize HIV management for patients with complex disease

PROGRAM DESCRIPTION

Patients with HIV have a life expectancy nearly equal to that of the general population, which means that clinicians must not only manage long-standing HIV but also recognize common comorbidities, such as cardiovascular disease, renal disease, osteoporosis or low bone mineral density, and neurocognitive disorders. Multidisciplinary care is the key to managing these aging patients, and all clinicians should be aware of the increased risks for comorbidities these patients face because of their HIV and because of unwanted effects of certain ART regimens. This series of interactive, short cases provides scenarios of patients with HIV and comorbidities to detail screening, routine monitoring, drug-drug interactions, and optimal switching strategies for commonly occurring comorbidities in aging patients with HIV.

FACULTY

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Integritas Communications. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

PHYSICIAN CONTINUING MEDICAL EDUCATION

The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

INSTRUCTIONS TO RECEIVE CREDIT

There are no fees for participating and receiving CME credit for this activity. During the period November 12, 2020 through November 12, 2021, participants must read the learning objectives and faculty disclosures and study the educational activity. 

A statement of credit will be issued only upon receipt of a completed activity evaluation form and posttest at the conclusion of the activity.

If you have questions regarding the receipt of your certificate, please contact PIM via email at inquiries@pimed.com.

DISCLOSURE OF CONFLICTS OF INTEREST

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Jonathan S. Appelbaum, MD, FACP, AAHIVS

Consulting fees: Merck & Co., Inc., ViiV Healthcare

Jeffrey Kwong, DNP, MPH, AGPCNP-BC, FAANP, FAAN                                                              

Consulting fees: Gilead Sciences, Inc.

The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

COURSE VIEWING REQUIREMENTS